Trigeminal Nueralgia Treatment

Trigeminal neuralgia (TN), also called tic douloureux, is a chronic pain condition that causes extreme, sporadic, sudden burning or shock-like face pain. The pain seldom lasts more than a few seconds or a minute or two per episode. The intensity of pain can be physically and mentally incapacitating. TN pain is typically felt on one side of the jaw or cheek. Episodes can last for days, weeks, or months at a time and then disappear for months or years. In the days before an episode begins, some patients may experience a tingling or numbing sensation or a somewhat constant and aching pain. The attacks often worsen over time, with fewer and shorter pain-free periods before they recur. The intense flashes of pain can be triggered by vibration or contact with the cheek (such as when shaving, washing the face, or applying makeup), brushing teeth, eating, drinking, talking, or being exposed to the wind. TN occurs most often in people over age 50, but it can occur at any age, and is more common in women than in men. There is some evidence that the disorder runs in families, perhaps because of an inherited pattern of blood vessel formation. Although sometimes debilitating, the disorder is not life-threatening.


The presumed cause of TN is a blood vessel pressing on the trigeminal nerve in the head as it exits the brainstem. TN may be part of the normal aging process but in some cases it is the associated with another disorder, such as multiple sclerosis or other disorders characterized by damage to the myelin sheath that covers certain nerves.


Is there any treatment?


Because there are a large number of conditions that can cause facial pain, TN can be difficult to diagnose. But finding the cause of the pain is important as the treatments for different types of pain may differ. Treatment options include medicines such as anticonvulsants and tricyclic antidepressants, surgery, and complementary approaches. Typical analgesics and opioids are not usually helpful in treating the sharp, recurring pain caused by TN. If medication fails to relieve pain or produces intolerable side effects such as excess fatigue, surgical treatment may be recommended. Several neurosurgical procedures are available. Some are done on an outpatient basis, while others are more complex and require hospitalization. Some patients choose to manage TN using complementary techniques, usually in combination with drug treatment. These techniques include acupuncture, biofeedback, vitamin therapy, nutritional therapy, and electrical stimulation of the nerves.


What is the prognosis?

The disorder is characterized by recurrences and remissions, and successive recurrences may incapacitate the patient. Due to the intensity of the pain, even the fear of an impending attack may prevent activity. Trigeminal neuralgia is not fatal.

How it works?

1.

Request for medicine

Patient who has serious problem request for medicine

 

2.

Drug Verify

Internal processing of drug verifications at GM Global

 

3.

Prescription

Recognizing best source for the specific prescription

 

4.

GDP Instruction

Import medicine under the GDP instruction

 

5.

QA check

Supply drugs to concerned healthcare provider after QA check

 

5.

QA check

Supply drugs to concerned healthcare provider after QA check

 

FAQ

A NPP provides access to post-approval drugs that are approved and commercially available in one or more country, other than the patient’s home country.

 

No. Companies are not required to provide their products through a formal NPP.

 

  • Dealing with unsolicited patient request for drug in an ethical and regulatory controlled manner
  • Providing exposure to, and experience with, company products to physicians in additional countries and build a larger KOL network and future advocates
  • Providing new products to patients who would move to commercial drug when it becomes available in these countries
  • Generating additional revenues in countries that allow you to charge for drugs supplied on a named patient basis

Companies can provide drug to patients in any country in which they have not yet received marketing approval. This includes countries in which a company plans to seek marketing approval, as well as those countries in which a company does not plan to seek marketing approval.

 
 

INFORMATION FOR PATIENTS

As a named patient medicines you may find yourself in the frightening position that you have a serious condition or illness and the treatment you need is not available in your home country. It is possible that the medicines are available outside your country and if your physician decides that these drugs would be suitable for the treatment of your illness, they then face the challenge of obtaining them for you. We help physicians across the world access medicines which are not approved or licensed in their country, but may be required to meet the special needs of an individual patient. The service we provide not only locates and supplies the required medicines but ensures that the physician has all the quality assurance and supporting clinical information they will need to safely prescribe it to you. If you are confronted with a situation where a drug is not available to you, talk to your physician or healthcare professional about Named Patient Program and ask them to contact us. We will then work directly with your physician to help them in patient access program and understand what options are available.

 

 

Drugs We Provide Under NPS

Drug Directory

Orphan Drugs

1.

Request for medicine

Patient who has serious problem request for medicine

 

2.

Drug Verify

Internal processing of drug verifications at GM Global

 

3.

Prescription

Recognizing best source for the specific prescription

 

4.

GDP Instruction

Import medicine under the GDP instruction

 

5.

QA check

Supply drugs to concerned healthcare provider after QA check

 

5.

QA check

Supply drugs to concerned healthcare provider after QA check

 

FAQ

A NPP provides access to post-approval drugs that are approved and commercially available in one or more country, other than the patient’s home country.

 

No. Companies are not required to provide their products through a formal NPP.

 

  • Dealing with unsolicited patient request for drug in an ethical and regulatory controlled manner
  • Providing exposure to, and experience with, company products to physicians in additional countries and build a larger KOL network and future advocates
  • Providing new products to patients who would move to commercial drug when it becomes available in these countries
  • Generating additional revenues in countries that allow you to charge for drugs supplied on a named patient basis

Companies can provide drug to patients in any country in which they have not yet received marketing approval. This includes countries in which a company plans to seek marketing approval, as well as those countries in which a company does not plan to seek marketing approval.

 
 

INFORMATION FOR PATIENTS

As a named patient medicines you may find yourself in the frightening position that you have a serious condition or illness and the treatment you need is not available in your home country. It is possible that the medicines are available outside your country and if your physician decides that these drugs would be suitable for the treatment of your illness, they then face the challenge of obtaining them for you. We help physicians across the world access medicines which are not approved or licensed in their country, but may be required to meet the special needs of an individual patient. The service we provide not only locates and supplies the required medicines but ensures that the physician has all the quality assurance and supporting clinical information they will need to safely prescribe it to you. If you are confronted with a situation where a drug is not available to you, talk to your physician or healthcare professional about Named Patient Program and ask them to contact us. We will then work directly with your physician to help them in patient access program and understand what options are available.